Sankary T; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 496 (abstract no. B.596).
AIDS Prevention Center, San Francisco, California, USA
OBJECTIVE: To assess the safety and efficacy of a new Chinese herbal immune enhancer developed in the People's Republic of China, which is produced from extracts of angelica, ginseng, and fructus lycium, in the treatment of early to mid-HIV infection. METHODS: 300 HIV seropositive patients with T4 helper lymphocyte counts between 100 and 600/mm3 and no prior HIV-related hospitalizations or ongoing treatments were randomized into double-blind treatment and placebo-controlled groups. The treatment group was given two Anginlyc 50 mg capsules three times a day. Diet instructions were to avoid lobster, shrimp, crab, bamboo shoots, duck, goose and alcohol. The placebo group received similar-looking capsules and instructions. All patients were followed at biweekly visits and monthly laboratory studies including CBC, chemistry panel, T and B lymphocyte panels and p24 antigen were performed. RESULTS: Symptom tabulation, labs, Karnofsky score, frequency of opportunistic infections, and HIV-related hospitalizations are analysed on a monthly basis over a 6 month period and summary statistics presented with multifactorial analysis. CONCLUSION: Promising non-western therapies for HIV infections deserve formal clinical trials in a randomized double-blind controlled fashion to evaluate their usefulness.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- CD4-Positive T-Lymphocytes
- China
- Double-Blind Method
- HIV Infections
- HIV Seropositivity
- Humans
- Karnofsky Performance Status
- therapy
Other ID:
UI: 102178477
From Meeting Abstracts